左心室尾关闭:治疗概述和未来的前景.
George H Nasr1, Parker M Rushworth1, David M Donaldson1
1Division of Cardiology, University of California, Irvine, 101 The City Drive South Suite 407, Orange, CA 92868, USA.
Cardiology clinics
|June 23, 2024
概括
左心房尾阻塞 (LAAO) 为心房动 (AF) 患者提供了一种中风风险降低策略,这些患者不适合抗凝药. 这篇评论涵盖了LAAO的解剖学,技术,结果和未来的潜力.
科学领域:
- 心脏病学 心脏病学
- 干预心脏病学 干预心脏病学
背景情况:
- 左心房附属体 (LAA) 是心房动 (AF) 中血栓栓塞事件的主要来源.
- 左心房尾阻塞 (LAAO) 是抗凝药的替代品,用于预防AF患者的中风.
- 对LAAO患者的选择至关重要,特别是对于那些对抗凝血药物有禁忌的人来说.
研究的目的:
- 为提供关于左心房尾闭塞 (LAAO) 的综合性综述.
- 讨论LAAO的解剖学考虑,程序技术和临床结果.
- 探索LAAO治疗的未来方向和进展.
主要方法:
- 对LAAO程序和结果的系统文献审查.
- 对关闭相关的LAA的解剖变异的分析.
- 评估当前的LAAO设备技术和植入技术.
主要成果:
- 在选定的AF患者中,LAAO有效降低了中风和全身栓塞的风险.
- 各种LAAO设备和技术显示出良好的安全性和有效性.
- 关于LAAO结果的长期数据仍在不断发展,目前正在研究最佳患者选择和设备创新.
结论:
- LAAO是一种可行且越来越多地用于预防AF患者中风的治疗选择.
- 持续的研究对于完善LAAO技术,设备技术和长期结果预测至关重要.
- 在心房动中,LAAO代表了管理血栓栓塞风险的重大进展.
相关概念视频
Mitral Regurgitation III: Medical Management
Mitral regurgitation (MR) is characterized by retrograde blood circulation from the left ventricle into the left atrium due to inadequate mitral valve closure. The severity of the condition, symptoms, and underlying cause determine treatment strategies.Monitoring and Pharmacological TreatmentPatients with mild to moderate MR typically do not need immediate intervention but regular monitoring to assess progression and guide treatment. Patients with mild MR should have an echocardiogram every 3-5...
Mitral Stenosis III: Medical Management
Mitral stenosis, a condition marked by the narrowing of the mitral valve, necessitates an integrated approach for effective management. This approach includes preventative measures, medical therapy, and surgical interventions to reduce symptoms and prevent complications.PreventionPrevention of mitral stenosis primarily focuses on reducing the incidence of bacterial infections, particularly streptococcal infections, which can lead to rheumatic fever and subsequent valvular damage. Timely...
Aortic Regurgitation III: Medical Management
Aortic regurgitation (AR) is when the aortic valve does not close or seal properly, leading to backward blood circulation from the aorta into the left ventricle during diastole. Common causes of AR include rheumatic heart disease, congenital valve defects, and aortic root dilation. Managing AR requires a multifaceted approach to alleviate symptoms, preserve left ventricular function, and address the underlying cause of the regurgitation. Patients with symptomatic AR or significant left...
Heart Failure VI: Adjunct Therapies
Additional therapies for treating patients with heart failure (HF) may include procedural interventions, supplemental oxygen, the management of sleep disorders, and nutritional therapy.Procedural InterventionsImplantable Cardioverter-Defibrillator: For patients at risk of life-threatening arrhythmias due to severe left ventricular dysfunction, an Implantable Cardioverter-Defibrillator (ICD) can detect and terminate these arrhythmias, preventing sudden cardiac death and improving survival rates.
Cardiomyopathy V: Interprofessional Care
Managing cardiomyopathy involves addressing underlying or precipitating causes, treating heart failure with medications, and implementing dietary changes and a balanced exercise and rest regimen.Lifestyle ModificationsCardiomyopathy patients should adopt a low-sodium diet to reduce fluid retention and manage heart failure. A personalized exercise and rest plan helps maintain physical fitness without overstraining the heart. Avoiding alcohol and tobacco is essential to prevent further damage to...


